Ginkgo Bioworks launches ADME-One, an AI-driven platform transforming early drug discovery with integrated ADME profiling.

Ginkgo Bioworks, in partnership with Tangible Scientific and Inductive Bio, has launched ADME-One, a fully integrated platform combining high-throughput ADME profiling, AI-driven human pharmacokinetic projections, and compound management. This innovation allows drug discovery teams to perform comprehensive ADME analysis earlier in the process, starting at hit identification, reducing costs and improving decision quality. The platform offers faster, standardized results from a U.S.-based automated lab, supporting better prioritization of drug candidates and accelerating development timelines. ADME-One aims to reshape small molecule drug discovery by integrating automation, AI, and streamlined logistics into one workflow.